Minerva Surgical, Inc. (UTRS)
| Previous Close | 0.0010 |
| Open | 0.0010 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0010 - 0.0010 |
| 52 Week Range | 0.0010 - 14.0000 |
| Volume | |
| Avg. Volume | 2,519 |
| Market Cap | 8,879 |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.6100 |
| Earnings Date | Apr 26, 2024 - May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
GlobeNewswireMinerva Surgical Reports Third Quarter 2023 Financial Results
SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023. Third Quarter Highlights: Reported revenue of $12.0 million in the third quarter of 2023, compared with revenue of $12.6 million in the third quarter of 2022Increased Symphion produc
ZacksMinerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue Estimates
Minerva Surgical, Inc. (UTRS) delivered earnings and revenue surprises of 44.44% and 3.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Minerva Surgical Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion an
